Enicepatide Delivers Glycemic and Weight Reduction in Phase 2

Company Roche Event Type Clinical Trial Data Readout Modality Peptide (Biased Dual Agonist) Asset Enicepatide (CT-388) Target GLP-1 / GIP receptors Disease Area Type 2 Diabetes Summary Roche reported that once weekly enicepatide met both primary endpoints in the randomized Phase 2 CT 388 104…